Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Richard D Francis is President and CEO at Teva Pharmaceutical Industries. OQRO lists 6 transactions filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
President and CEO
Disclosures on record
6
Companies involved
1
Teva Pharmaceutical IndustriesTEVA
6 disclosures · Feb 2025 – Nov 2026 · 6 sold
Nov 10, 2026Sold~$10.6Mdisclosed Nov 12
DetailsOfficial recordMar 4, 2025Sold~$244Kdisclosed Mar 6
Mar 5, 2025Sold~$131Kdisclosed Mar 6
DetailsOfficial recordMar 3, 2025Sold~$403Kdisclosed Mar 5
DetailsOfficial recordMar 4, 2025Sold~$100Kdisclosed Mar 5
DetailsOfficial recordFeb 18, 2025Sold~$1.28Mdisclosed Feb 19
DetailsOfficial recordAs of the latest filing on , Richard D Francis reported holding 927,529 shares of Teva Pharmaceutical Industries (TEVA), worth about $41.3M at the last close of $45 (Nov 13, 2026). In the last 12 months, Richard D Francis sold $10.6M in 1 sale.
Teva Pharmaceutical Industries's proxy statement reports total compensation of $19.2M for Richard D Francis for fiscal year 2025, after $15.5M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Mar 31, 2026
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries TEVA | 927,529 | 928K direct | $45 | $41.3M | Nov 10, 2026 |
Is this Richard D Francis’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Richard D Francis bought shares on the open market in 2017, and has not bought since 2017 across 2 companies. Sales in each of the last 3 years.
Richard D Francis reported 1 open-market purchase and 8 sales since 2017; purchases in 2017.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $10.6M1×1 trade |
| 2025 | — | $2.16M5×5 trades |
| 2024 | — | $1.39M2×2 trades |
| 2017 | $100K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 10, 2026, Richard D Francis reported holding 927,529 shares of Teva Pharmaceutical Industries (TEVA). At the last close of $45 on Nov 13, 2026, that is about $41.3M. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Richard D Francis reported 1 open-market sale worth $10.6M, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Teva Pharmaceutical Industries's proxy statement reports total compensation of $19.2M for Richard D Francis for fiscal year 2025, after $15.5M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Richard D Francis bought shares on the open market in 2017, and has not bought since 2017 across 2 companies. Sales in each of the last 3 years.
In SEC filings since 2017: the latest open-market purchase is from 2017; the latest open-market sale is from 2026.
2 companies: Teva Pharmaceutical Industries (TEVA, 2024–2026), Mettler Toledo (MTD, 2017).
Richard D Francis reported 0 open-market purchases and 8 sales here, 2024 to 2026.
Richard D Francis reported 1 open-market purchase and 0 sales here, 2017.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
